 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...63646566676869707172737475» |
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: IRay to Treat Polypoidal Choroidal Vasculopathy (PCV) Secondary to Age-Related Macular Degeneration (AMD (clinicaltrials.gov) - Jul 26, 2012
P=N/A, N=12, Active, not recruiting, Sponsor: Oraya Therapeutics, Inc.
Recruiting --> Active, not recruiting
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion, HEOR: SALUTE: Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Jul 23, 2012
P4, N=99, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Surgery: Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery (clinicaltrials.gov) - Jul 23, 2012
P1, N=5, Completed, Sponsor: Bascom Palmer Eye Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Ranibizumab for the Inhibition of Neovascularization in Pterygia (clinicaltrials.gov) - Jul 23, 2012
P1, N=10, Completed, Sponsor: Bascom Palmer Eye Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
Trial termination: SEAGUL: Study Evaluating Genotypes Using Lucentis (clinicaltrials.gov) - Jul 12, 2012
P4, N=65, Terminated, Sponsor: University of Utah
Active, not recruiting --> Completed Completed --> Terminated; IND holder relocated from the University of Utah
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
New P2/3 trial: Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME) (clinicaltrials.gov) - Jul 8, 2012
P2/3, N=246, Recruiting, Sponsor: Prof. dr. R.O. Schlingemann
- Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Trial completion: PBS: Photodynamic and Pharmacologic Treatment of CNV (clinicaltrials.gov) - Jul 5, 2012
P1/2, N=41, Completed, Sponsor: Mid-Atlantic Retina Consultations, Inc.
Completed --> Terminated; IND holder relocated from the University of Utah Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks (clinicaltrials.gov) - Jun 27, 2012
P1/2, N=0, Withdrawn, Sponsor: University of Illinois at Chicago
Active, not recruiting --> Completed N=10 --> 0
- || Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
New P2/3 trial: Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO) (clinicaltrials.gov) - Jun 27, 2012
P2/3, N=296, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - Jun 27, 2012
P1/2, N=10, Active, not recruiting, Sponsor: University of Illinois at Chicago
N=10 --> 0 Recruiting --> Active, not recruiting
- Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration (clinicaltrials.gov) - Jun 24, 2012
P4, N=49, Completed, Sponsor: University of Melbourne
- || Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New P3 trial, HEOR: Protocol T: Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema (clinicaltrials.gov) - Jun 21, 2012
P3, N=660, Active, not recruiting, Sponsor: Diabetic Retinopathy Clinical Research Network
- |||| Fovista (pegpleranib) / Roche, Astellas
Trial completion, Combination therapy: A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Jun 13, 2012
P2, N=449, Completed, Sponsor: Ophthotech Corporation
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion (clinicaltrials.gov) - Jun 4, 2012
P=N/A, N=30, Recruiting, Sponsor: Brian Burke, MPH
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: RACE: Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration (clinicaltrials.gov) - Jun 3, 2012
P2, N=99, Completed, Sponsor: Alcon Research
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
New P2 trial: Ranibizumab and Bevacizumab for Diabetic Macular Edema (clinicaltrials.gov) - May 31, 2012
P2, N=67, Recruiting, Sponsor: National Eye Institute (NEI)
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: PEARL: Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) (clinicaltrials.gov) - May 31, 2012
P1, N=17, Completed, Sponsor: Hawaii Pacific Health
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis, Macugen (pegaptanib) / Bausch Health
Trial completion: Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis (clinicaltrials.gov) - May 23, 2012
P2, N=100, Completed, Sponsor: Retina Institute of Hawaii
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: FVF4153s: Lucentis for Treatment of Macular Edema (clinicaltrials.gov) - May 23, 2012
P=N/A, N=30, Completed, Sponsor: Retina Institute of Hawaii
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema (clinicaltrials.gov) - May 22, 2012
P2, N=49, Completed, Sponsor: Rocky Mountain Retina Consultants
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
New P3 trial, Monotherapy: Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion (clinicaltrials.gov) - May 14, 2012
P3, N=454, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- Lucentis (ranibizumab) / Roche, Novartis
Trial withdrawal: Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) (clinicaltrials.gov) - May 9, 2012
P1, N=0, Withdrawn, Sponsor: University of California, San Diego
Active, not recruiting --> Completed Recruiting --> Withdrawn
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) (clinicaltrials.gov) - May 9, 2012
P1, N=0, Withdrawn, Sponsor: University of California, San Diego
Recruiting --> Withdrawn N=10 --> 0
- Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Trial withdrawal, Monotherapy: Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - May 8, 2012
P=N/A, N=0, Withdrawn, Sponsor: Lahey Clinic
N=10 --> 0 Active, not recruiting --> Withdrawn
- Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Enrollment change, Monotherapy: Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD) (clinicaltrials.gov) - May 8, 2012
P=N/A, N=0, Withdrawn, Sponsor: Lahey Clinic
Active, not recruiting --> Withdrawn N=20 --> 0
- ||||| Lucentis (ranibizumab) / Roche, Novartis
New P4 trial, Combination therapy: Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE) (clinicaltrials.gov) - May 7, 2012
P4, N=120, Recruiting, Sponsor: Novartis Pharmaceuticals
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Metastases: Lucentis in Advanced Macular Degeneration (clinicaltrials.gov) - Apr 29, 2012
P2, N=20, Active, not recruiting, Sponsor: Steven R. Sanislo
N=20 --> 0 N=40 --> 20
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Metastases: Lucentis in Advanced Macular Degeneration (clinicaltrials.gov) - Apr 29, 2012
P2, N=20, Active, not recruiting, Sponsor: Steven R. Sanislo
N=40 --> 20 Recruiting --> Active, not recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma (clinicaltrials.gov) - Apr 24, 2012
P1, N=10, Completed, Sponsor: The New York Eye Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed, Monotherapy: Macular EpiRetinal Brachytherapy Versus Lucentis (clinicaltrials.gov) - Apr 18, 2012
P4, N=363, Active, not recruiting, Sponsor: King's College Hospital NHS Trust
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Lucentis (ranibizumab) / Roche, Novartis
New P4 trial: Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO (clinicaltrials.gov) - Apr 16, 2012
P4, N=180, Recruiting, Sponsor: Novartis Pharmaceuticals
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: DETAIL: Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments (clinicaltrials.gov) - Apr 9, 2012
P2/3, N=15, Completed, Sponsor: Pacific Eye Associates
Recruiting --> Active, not recruiting N=20 --> 15
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration (clinicaltrials.gov) - Apr 9, 2012
P2, N=40, Active, not recruiting, Sponsor: Anne Fung MD
N=20 --> 15 Recruiting --> Active, not recruiting
- || Lucentis (ranibizumab) / Roche, Novartis
Trial completion: DETAIL: Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments (clinicaltrials.gov) - Apr 9, 2012
P2/3, N=15, Completed, Sponsor: Pacific Eye Associates
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Vascular Endothelial Growth Factor (VEGF) & LOC387715/HTRA1 Polymorphism in Polypoidal Choroidal Vasculopathy (clinicaltrials.gov) - Apr 5, 2012
P=N/A, N=121, Completed, Sponsor: Kyungpook National University
Active, not recruiting --> Completed N=70 --> 121
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Vascular Endothelial Growth Factor (VEGF) & LOC387715/HTRA1 Polymorphism in Polypoidal Choroidal Vasculopathy (clinicaltrials.gov) - Apr 5, 2012
P=N/A, N=121, Completed, Sponsor: Kyungpook National University
N=70 --> 121 Recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II) (clinicaltrials.gov) - Mar 29, 2012
P2, N=6, Completed, Sponsor: Jumper, J. Michael, M.D.
Recruiting --> Completed N=15 --> 6
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II) (clinicaltrials.gov) - Mar 29, 2012
P2, N=6, Completed, Sponsor: Jumper, J. Michael, M.D.
N=15 --> 6 Recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
Trial termination, Monotherapy: RELATION: Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (clinicaltrials.gov) - Mar 28, 2012
P3, N=128, Terminated, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Recruiting --> Terminated; European drug approval.
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Monotherapy: RELATION: Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (clinicaltrials.gov) - Mar 28, 2012
P3, N=128, Terminated, Sponsor: Novartis Pharmaceuticals
Recruiting --> Terminated; European drug approval. N=300 --> 128
- Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Enrollment change: CLOVER: Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment (clinicaltrials.gov) - Mar 26, 2012
P4, N=10, Completed, Sponsor: Illinois Retina Associates
N=300 --> 128 N=20 --> 10
- | Lucentis (ranibizumab) / Roche, Novartis, iCo-007 / Ionis
New P2 trial, Combination therapy, Monotherapy: iDEALt: A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study) (clinicaltrials.gov) - Mar 26, 2012
P2, N=208, Active, not recruiting, Sponsor: Quan Dong Nguyen
- Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Trial completion: CLOVER: Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment (clinicaltrials.gov) - Mar 26, 2012
P4, N=10, Completed, Sponsor: Illinois Retina Associates
N=20 --> 10 Recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Surgery: Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery (clinicaltrials.gov) - Mar 25, 2012
P1, N=4, Completed, Sponsor: Bhagat, Neelakshi, M.D., M.P.H.
Recruiting --> Completed N=10 --> 4
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Surgery: Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery (clinicaltrials.gov) - Mar 25, 2012
P1, N=4, Completed, Sponsor: Bhagat, Neelakshi, M.D., M.P.H.
N=10 --> 4 Active, not recruiting --> Completed
- Humira (adalimumab) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (clinicaltrials.gov) - Mar 15, 2012
P2, N=5, Completed, Sponsor: Hospital Universitari Vall d'Hebron Research Institute
Active, not recruiting --> Completed N=12 --> 5
- Humira (adalimumab) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (clinicaltrials.gov) - Mar 15, 2012
P2, N=5, Completed, Sponsor: Hospital Universitari Vall d'Hebron Research Institute
N=12 --> 5 Recruiting --> Completed
- | Lucentis (ranibizumab) / Roche, Novartis
New P2 trial: The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema (clinicaltrials.gov) - Mar 13, 2012
P2, N=20, Recruiting, Sponsor: Moorfields Eye Hospital NHS Foundation Trust
- | Lucentis (ranibizumab) / Roche, Novartis
New P1/2 trial, Monotherapy: Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE) (clinicaltrials.gov) - Mar 11, 2012
P1/2, N=40, Recruiting, Sponsor: David M. Brown, M.D.
- Ozurdex (dexamethasone intravitreal implant) / AbbVie
Trial termination: Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration (clinicaltrials.gov) - Mar 6, 2012
P2, N=4, Terminated, Sponsor: Allergan
Recruiting --> Completed Active, not recruiting --> Terminated; The study was terminated early due to difficulties with patient recruitment.